// App-Quantinova.ai

e24109 : High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).

Researchers

Presenter

  • Vaia Florou

Principal Investigators

  • Wungki Park

  • Alfredo Enrique Torres

  • Sandra Algaze

  • Diana Saravia

  • Breelyn A. Wilky

  • Jaime R. Merchan

  • Peter Joel Hosein

  • Albert Craig Lockhart

  • Gilberto Lopes

Medical Centers

  • University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL

  • University of Miami/Sylvester Cancer Center, Miami, FL

  • University of Miami, Department of Medicine, Miami, FL

  • Jackson Memorial Hospital, University of Miami, Miami, FL

  • UM Sylvester Comprehensive Cancer Center, Deerfield Beach, FL

  • University of Miami, Miami, FL

  • University of Miami/Sylvester Cancer Center, Miami, FL

  • Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Neutrophil lymphocyte ratio

  • X-Ray Repair Cross Complementing 1

  • Tumor mutational burden

Drug/Treatment

  • Pembrolizumab

  • Atezolizumab

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved